<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05122507</url>
  </required_header>
  <id_info>
    <org_study_id>KOHACIN</org_study_id>
    <nct_id>NCT05122507</nct_id>
  </id_info>
  <brief_title>Liquid Biopsy of Head and Neck Cancer Patients in Blood and Saliva</brief_title>
  <acronym>KOHACIN</acronym>
  <official_title>Liquid Biopsy of Head and Neck Cancer Patients in Blood and Saliva</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective study for therapy monitoring of locally advanced and metastatic head and neck&#xD;
      cancer patients by detection of circulating tumor nucleic acids in peripheral blood and&#xD;
      saliva&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical examination including imaging and - if necessary - tissue biopsy sampling - is the&#xD;
      current clinical standard in therapy monitoring of metastatic head and neck tumors. This&#xD;
      includes both the initial diagnosis, the assessment of the therapeutic response during&#xD;
      ongoing chemotherapy / radiochemotherapy and follow-up care with the aim of detecting&#xD;
      recurrences at an early stage. The detection of circulating nucleic acids as well as proteins&#xD;
      in the peripheral blood and saliva could represent a minimally invasive and exact method for&#xD;
      the assessment of the tumor burden, for the early detection of recurrences and for the&#xD;
      individual assessment of the therapy response in patients with head and neck cancer. The&#xD;
      present study aims to evaluate the value of tumor-specific nucleic acids and proteins in&#xD;
      peripheral blood and saliva as possible biomarkers for minimally invasive therapy monitoring&#xD;
      of head and neck tumors. For this purpose, Next Generation Sequencing (NGS), ELISA and&#xD;
      quantitative polymerase chain reaction (PCR) methods are used as diagnostic methods. NGS&#xD;
      initially enables the creation of a genetic profile of the primary tumor with targeted&#xD;
      massive parallel sequencing of frequently mutated genes in head and neck tumors. The amount&#xD;
      of nucleic acids in the peripheral blood and saliva is then quantified by means of digital&#xD;
      PCR with the aid of specifically designed digital PCR assays. In addition, tumor-associated&#xD;
      nucleic acids and proteins in the primary tumor, blood and saliva are examined. The aim is to&#xD;
      examine if the amount of tumor specific circulating nucleic acids and the concentration of&#xD;
      protein biomarkers found in the blood and saliva are associated with the response to&#xD;
      treatment, early detection of recurrence, and the overall prognosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2017</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Early recurrence detection lead time</measure>
    <time_frame>Assessed up to 24 months</time_frame>
    <description>Lead time is defined as time between liquid-biopsy based recurrence detection and clinical recurrence or progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>Assessed up to 24 months</time_frame>
    <description>Recurrence-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Assessed up to 24 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor tissue, EDTA blood plasma, serum, saliva&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated for HNSCC at Klinikum rechts der Isar der Technischen Universität München&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Head and neck squamous cell carcinoma (HNSCC)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neoplasms other than HNSCC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irina Kerle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universität München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Markus Wirth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universität München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christof Winter, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universität München</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus Wirth, MD</last_name>
    <phone>+49 89 4140</phone>
    <phone_ext>9416</phone_ext>
    <email>markus.wirth@tum.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christof Winter, MD, PhD</last_name>
    <phone>+49 89 4140</phone>
    <phone_ext>4765</phone_ext>
    <email>christof.winter@tum.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der Technischen Universität München</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Wirth, MD</last_name>
      <phone>+49 89 4140</phone>
      <phone_ext>9416</phone_ext>
      <email>markus.wirth@tum.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liquid Biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

